Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin

Molecular Cancer Therapeutics

Volumn 7, Issue 7, 2008, Pages 2152-2159

  Kovalchuk, Olga ^a   Filkowski, Jody ^a   Meservy, James ^a   Ilnytskyy, Yaroslav ^a   Tryndyak, Volodymyr P ^b   Chekhun, Vasyl F ^c   Pogribny, Igor P ^b  

^a UNIVERSITY OF LETHBRIDGE   (Canada)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

[No Author keywords available]

Indexed keywords

ARGONAUTE 2 PROTEIN; DICER; DOXORUBICIN; MICRORNA; EIF2C2 PROTEIN, HUMAN; GLYCOPROTEIN P; INITIATION FACTOR 2; MICRORNA 451, HUMAN; MICRORNA-451, HUMAN; RIBONUCLEASE III;

ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER RESISTANCE; CELL STRAIN MCF 7; DRUG SENSITIVITY; GENETIC CORRELATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROCESSING; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; TUMOR CELL LINE;

BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; EUKARYOTIC INITIATION FACTOR-2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR SEQUENCE DATA; P-GLYCOPROTEIN; RIBONUCLEASE III;

EID: 51049104524     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0021     Document Type: Article

References (50)

1. Lehnert M. Chemotherapy resistance in breast cancer. Anticancer Res 1998;18:2225-6.
2. Szakacs G, Paterson JK, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Disc 2006;5:219-34.
3. Cox MC, Dan TD, Swain SM. Emerging drugs to replace current leaders in first-line therapy for breast cancer. Expert Opin Emerg Drugs 2006;11:489-501.
4. Roberti A, La Sala D, Cinti C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol 2006;207:571-81.
5. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006;94:1087-92.
6. Iwasa Y, Nowak MA, Michor F. Evolution of resistance during clonal expansion. Genetics 2006;172:2557-66.
7. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Res Update 2007;10:59-67.
8. Duesberg P, Li R, Sachs R, Fabarius A, Upender MB, Hehlmann R. Cancer drug resistance: the central role of the karyotype. Drug Res Update 2007;10:51-8.
9. Matarazzo MR, Boyle S, D'Esposito M, Bickmore WA. Chromosome territory reorganization in human disease with altered DNA methylation. Proc Natl Acad Sci U S A 2007;104:16546-51.
10. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
11. Sevignani C, Calin GA, Siracusa LD, Croce CM. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome 2006;17:189-202.
12. Bushati N, Cohen SM. microRNAs functions. Annu Rev Cell Dev Biol 2007;23:175-205.
13. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
14. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
15. Iorio MV, Ferracin M, Liu C-G, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70.
16. Blenkiron C, Goldstein LD, Thorne NP, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumour subtype. Genome Biol 2007;8:R214.
17. Tricoli JV, Jacobson JW. MicroRNA: potential for cancer detection, diagnosis, and prognosis. Cancer Res 2007;67:4553-5.
18. Blenkiron C, Miska EA. miRNAs in cancer: approaches, aetiology, diagnostics and therapy. Hum Mol Genet 2007;16:R106-13.
19. Climent J, Dimitrow P, Fridlyand J, et al. Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res 2007;67:818-26.
20. Chekhun VF, Lukyanova NYu, Kovalchuk O, Tryndyak VP, Pogribny IP. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol Cancer Ther 2007;6:1089-98.
21. Bolstad BM, Irizarry RA, Astrandand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93.
22. Eisen MB, Spellman PT, Brown PO, Boltstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
23. -ΔΔCt method. Methods 2001;25:402-8.
24. Chiosea S, Jelezcova E, Chandran U, et al. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res 2007;67:2345-50.
25. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007;39:673-7.
26. Schmitter D, Filkowski J, Sewer A, et al. Effects of Dicer and Argonaute down-regulation on mRNA levels in human HEK293 cells. Nucleic Acids Res 2006;34:4801-15.
27. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006;9:435-43.
28. Welch C , Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007;26:5017-22.
29. Fukuda Y, Kawasaki H, Taira K. Exploration of human miRNA target genes in neuronal differentiation. Nucleic Acids Symp Ser 2005;49:341-2.
30. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 2006;66:9090-8.
31. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-47.
32. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-α (ERα) and represses ERα messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 2007;21:1132-47.
33. Volinia S, Calin G, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61.
34. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133:647-58.
35. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68:425-33.
36. Hurteau GJ, Carlson A, Spivack SD, Brock GJ. Overexpression of the microRNA has-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007;67:7972-6.
37. Ma L, Teruya-Feldstein J, Weinberg RA. Tumor invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007;449:682-8.
38. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008;18:350-9.
39. Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 2006;580:998-1009.
40. Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 2006;12:273-86.
41. Baker EK, El-Osta A. MDR1, chemotherapy and chromatin remodeling. Cancer Biol Ther 2004;3:819-24.
42. David GL, Yegnasubramanian S, Kumar A, et al. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells. Cancer Biol Ther 2004;3:540-8.
43. Megraw M, Sethupathy P, Corda B, Hatzigeorgiou AG. miRGen: a database for the study of animal microRNA genomic organization and function. Nucleic Acids Res 2007;35:D149-55.
44. Lowery AJ, Miller N, McNeil RE, Kerin MJ. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res 2008;14:360-5.
45. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88:1285-91.
46. ILage H. MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr Drug Targets 2006;7:813-21.
47. Kaszubiak A, Holm PS, Lage H. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes. Int J Oncol 2007;31:419-30.
48. Weidhaas JB, Babar I Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 67:11111-6.
49. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3° and 3B. Proc Natl Acad Sci U S A 2007;104:15805-10.
50. Klein ME, Lioy DT, Ma L, Impey S, Mandel G, Goodman RH. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat Neurosci 2007;10:1513-4.